Cautious Hold Rating on Merus Amid Genmab Acquisition Uncertainty and Promising Pipeline

William Blair analyst Matt Phipps has maintained their neutral stance on MRUS stock, giving a Hold rating on October 24.

Matt Phipps has given his Hold rating due to a combination of factors surrounding Merus’s current situation. The primary reason is the ongoing acquisition by Genmab, which was announced for approximately $8 billion. This acquisition adds significant value to Merus’s late-stage pipeline, especially with the promising potential of petosemtamab, which has shown initial efficacy in colorectal cancer.
Despite the promising data, the acquisition’s completion is pending, and the uncertainty surrounding the finalization of this deal warrants a cautious approach. The Hold rating reflects the need to wait for more concrete developments regarding the acquisition and further validation of the pipeline’s potential before making a more decisive investment recommendation.

In another report released on October 24, BMO Capital also maintained a Hold rating on the stock with a $97.00 price target.